MissionIR Small-Cap Investor Blog: March 2014

Friday, March 28, 2014

VolitionRx Ltd. (VNRX) Cancer Diagnostic Tool Yield Hope amid Global Epidemic of Prostate Cancer

Life sciences company VolitionRx is engaged in the development of blood-based diagnostic tests for different types of cancer. Demonstrating significant headway with its NuQ® assays, VolitionRx recently released data from a pilot study of the test to diagnose prostate cancer.

Results from the trial show that NuQ assays were able to detect roughly 80 percent of prostate cancer cases and also has the ability to differentiate between colorectal and prostate cancer.

As VolitionRx continues to develop its NuQ tests, it’s impossible to ignore the global need for such technology and the value of the company’s ongoing research and development initiatives.

More than 1.1 million cases of prostate cancer were recorded in 2012, accounting for approximately 8 percent of all new cancer cases and 15 percent of cancer in men, according to the latest figures from the World Cancer Research Fund International.

Furthermore, prostate cancer is the most frequently diagnoses non-skin cancer in the United States, and the third leading cause of cancer deaths in the nation, reports the National Institutes of Health (NIH). An NIH online report entitled “The Worldwide Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies,” concludes in recognition of the value of accurate diagnostics.

“The clinical incidence, mortality, and to a lesser degree prevalence of prostate cancer varies among various geographical regions of the world. The approach to screening, early detection initiatives, and availability of treatment modalities has a major impact on disease epidemiology.”

By detecting two major cancers with a blood test, VolitionRx has not only achieved an important company milestone, but has also warranted further investigation for panels of its NuQ tests as a cancer diagnostic tool.

For more information, visit www.volitionrx.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Florida Hospital Memorial Medical Center Employs Authentidate Holding Corp. (ADAT) InscrybeMD Telehealth Remote Monitoring Solution

Authentidate Holding, a provider of secure web-based software applications and telehealth products and services for the healthcare industry, reports that Florida Hospital Memorial Medical Center has selected the Authentidate InscrybeMD® telehealth solution using the Electronic House Call™ device (EHC) to remotely provide clinical services to their patients.

Using the InscrybeMD telehealth solution, Florida Hospital will be able to provide patients that require regular monitoring of medical conditions with the follow-up care necessary to manage their disease and/or condition. The EHC device provides frequent updates of patient data to healthcare providers without a face-to-face visit, reducing costs while supporting improved patient health outcomes.

The EHC touch screen device delivers automated reminders to increase patients’ compliance with care plans, diets, medication schedules, and follow-up physician visits. Healthcare providers can view each patient’s vital statistics and make adjustments to care plans on the secure InscrybeMD web application, which is then communicated to the patient via the EHC device during scheduled sessions. EHC also provides patients with disease management education that their clinician selects for them to view on the EHC device.

“The InscrybeMD telehealth solution has proven highly effective at keeping patients on their care plans, improving patient outcomes and reducing readmissions at similar healthcare organizations. We are committed to improving the health of our patients and providing the tools necessary for our clinical staff to accomplish that goal,” Jill Piazza, PT, DPT, director of health and performance at Florida Hospital Memorial Medical Center stated in the news release.

The InscrybeMD solution can also be used for a number of other patient illnesses, behavioral health conditions, and wellness programs that require ongoing clinical management to encourage healthier life habits and overall improved health.

“We are seeing increased interest from healthcare organizations like Florida Hospital Memorial Medical Center to improve their patients’ health outcomes and reduce readmissions with our InscrybeMD telehealth solutions. We are thrilled that Florida Hospital has entrusted us to help them deliver on their goals and look forward to empowering them to do so through the use of our EHC devices and InscrybeMD web application,” said Jessica Levenberg, sales director at Authentidate.

For more information, visit www.authentidate.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, March 27, 2014

VistaGen Therapeutics, Inc. (VSTA) Impressive in Predicting Test Outcomes of Vital Drug Candidates

VistaGen Therapeutics is keenly aware that despite decades of well-intentioned awareness and prevention campaigns, heart disease is still the leading cause of death for both men and women. The disease kills more than 600,000 Americans each year. According to the Center for Disease Control, approximately 49 percent of Americans have at least one of the three risk factors for heart disease – these being high blood pressure, high LDL cholesterol, and smoking. Despite researcher insights concluding that an overwhelming majority of heart disease is the result of poor lifestyle choices, scientists understand the statistics are dynamic in nature and must be constantly monitored.

VistaGen is a life sciences company that innovatively leverages its Human Clinical Trials in a Test Tube™ technology platform to provide clinically relevant predictions of potential toxicity of promising new drug candidates. Cardiovascular care is one of VistaGen’s particular areas of focus.

Unexpected safety concerns are pointed to as the reason why about one-third of all potential new drug candidates fail in preclinical or clinical development. It is believed that many lives could have been saved if it were not for promising cardiovascular drugs being discontinued because of late-stage failure. Using human heart cells derived from human pluripotent stem cells (hPSCs), VistaGen’s technology is designed to address potential toxicity of new cardiovascular drug candidates long before they are ever tested in humans.

CardioSafe 3D™, the company’s novel three-dimensional (3D) bioassay system, was developed to identify safer drug rescue variants with reduced heart safety concerns, which can be missed in animal models or in vitro cell culture testing currently used by biotechnology and pharmaceutical companies.

VistaGen’s plan is to combine CardioSafe 3D™ with modern medicinal chemistry to build a pipeline of safer chemical variants (Drug Rescue Variants™) of once-promising drug candidates that initially were developed by biotechnology and pharmaceutical companies, but were abandoned later due to the concerns mentioned earlier. Other notable work involves AV-101, the company’s lead small molecule drug candidate. The drug has successfully completed Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects millions of people worldwide. VSTA believes its Phase 1 safety program will enable Phase 2 development of AV-101 for neuropathic pain, depression, and potentially other neurological conditions. To date, VistaGen has been awarded over $8.8 million from the NIH for development of AV-101.

The core goal is to license or sell Drug Rescue Variants to biotechnology and pharmaceutical companies for further development and commercialization. VistaGen believes its strategy has the potential to substantially reduce drug development costs and produce effective and safer drugs, which would inherently help save human lives.

For more information visit www.vistagen.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Tuesday, March 25, 2014

China Housing & Land Development, Inc. (CHLN) Announces Authorization of New $10 Million Share Repurchase Program

Today, China Housing & Land Development announced that its board of directors had authorized a new share repurchase program. In the program, the company will be able to repurchase up to $10 million shares of common stock.

China Housing & Land Development is the first and only Chinese real estate development company that is being traded on the NASDAQ. Located in Xi’an, the capital city of China’s Shaanxi province, the company focuses on the development of commercial and residential properties in northwest China. Since its founding in 1992, China Housing & Land Development has been involved in land acquisitions, development efforts, and property management, inclusive of commercial and residential property sales conducted through its wholly owned subsidiary.

Mr. Pingji Lu, China Housing’s Chairman of the Board commented, “We continue to believe that our current share price does not fully reflect the true market value of China Housing and are pleased that our Board has authorized a new share repurchase program. As of December 31, 2013, the Company has repurchased a total of 1,166,369 shares under the $5 million share repurchase program announced on August 11, 2011. We are pleased to implement another share repurchase program as we continue to believe the repurchase program is a good investment of available funds and underscores our commitment to enhancing shareholder value.”

In the program, the company’s common stock shares will be purchased at different times in open market transactions or in privately negotiated transactions at the company’s discretion, per SEC and NASDAQ requirements and subject to market conditions and other influences. China Housing & Land Development stipulated that there is no guarantee as to what the exact number of shares it repurchases will be, and that it may discontinue the sale should its board of directors find additional purchases unwarrantied.

More information about China Housing & Land Development and its plans for targeting key locations in western China can be found at: http://www.chldinc.com.

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Methes Energies International Ltd. (MEIL) on Schedule with Denami Sales Growth

Methes Energies recently announced reception of a deposit from island-based biodiesel project developer, Antilla Energy VBA (formerly BioFuel Aruba), to start manufacturing a new Denami 600 unit destined for one of Antilla’s facilities in Aruba. MEIL is a provider of a range of products and services to the biodiesel sector. These products include, but are not limited to, low-cost, fully-automated continuous flow biodiesel processors that are able to run on a wide variety of feedstocks. These processors are formally known as the Denami 600 and Denami 3000.

Scheduled for delivery by September 2014, the new Denami 600 unit will be used to process locally collected waste cooking oil, which will then be blended with diesel before being distributed island-wide. Biodiesel activist and Managing Director of Antilla Energy, Gregory Fung-A-Fat, explained that while there was an extensive due diligence process, Antilla is now ready for their first Denami from Methes and they are well positioned for future purchases of several additional units.

With the first Denami 600 unit anticipated to produce six million gallons per year for Antilla at their Aruba location, there are four additional units slated for activation pending market conditions conducive to their implementation. Director, Fung-A-Fat assured markets that Antilla was already poised to execute on growth of their production plans via new Denami hardware acquisitions in a cost effective manner.

The company’s clientele benefits from a unique business model, which is comparable to the support provided in the fast food business by the Franchisor. Methes provides its clients with comprehensive support and assistance throughout the necessary steps involved in setting up their facility. These steps include obtaining permits, acquiring government incentives, and site layout planning, to name a few. Subsequently, MEIL helps its clients with the day-to-day operation of their business by providing everything needed for their biodiesel production, including feedstock, methanol, and catalyst. The company also handles the sale of its clients’ biodiesel production. Complemented with a full-time remote online monitoring system, the company contends there is no other equipment provider who can claim this type of support.

For more information about the company visit www.Methes.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Monday, March 24, 2014

Mountain Province Diamonds Inc. (MDM) On-Schedule at Gahcho Kue JV Project with De Beers in Canada’s Northwest Territories, Update Indicates

Mountain Province Diamonds, which is 49% joint-ventured up with the Canadian arm of the world’s leading diamond company, De Beers, on the planet’s largest new diamond mine, the 10.35k-acre Gahcho Kue project at Kennady Lake up in the Northwest Territories (just 66 miles east of De Beers’ Snap Lake diamond mine on federal lands), took some time out today to update markets on the healthy status of the project’s development.

With everything on-track for a production start by Q3 2016, Gahcho Kue stood at 17% completion with the close of last month and both parties have been noted by De Beers as being quite happy with overall progress to date. Confidence is running high in the JV with no changes to their projected development schedule. The full Land Use Permit and Class A Water Rights look well in hand for the target date of sometime in the second half of this year and we should see a feasibility update by the end of March. The feasibility update will have the latest reserve statement, as well as timely capital/operating cost estimates and the latest project economics, with additional details on project financing emerging as the study becomes available.

Equipment and supplies have been steadily streaming into the site over the 2014 ice road, with some 670 truckloads having already arrived and another 100 set for the end of the month. The JV now has roughly 120 people on-site prepping and this number will definitely rise as the year advances, with a 700-person target set for the peak construction interval. All work to date has been free of any lost-time injuries and the JV already has the prefab units on-site for their main camp. With the airstrip construction started and a usage target for both the airstrip and the main camp set for around the middle of the year, things are now really starting to pick up at Gahcho Kue.

They have eight large (17.7 cubic feet each) fuel tanks installed and construction of two even larger tanks has commenced (63.6k cubic feet each), with fuel stockpiling towards a twelve-month operational window already under way. Deep drilling efforts have been brisk, with the first three holes at the Tuzo Pipe targeting approximately 2,460-foot depths started last month and subsequently sticking at around the 1,300-foot mark. They are currently still going at the first hole via a wedge re-drill about 300 feet up and have now brought in a second rig to expedite the process, leaving markets to lick their lips over a forthcoming update on more details of their drilling progress.

There are four distinct diamondiferous kimberlites at Gahcho Kue (5034, Hearne, Tuzo and Telsa) and while the smaller Tesla target is not in the mine plan (only about an acre), it will likely be exploited towards the end of the mine’s life. The three primary targets at Gahcho Kue contain a probable mineral reserve of some 31.3M tonnes at 1.57 carats per tonne (49M CT total). All data contained in today’s update was prepared under supervision of NI 43-101 Qualified Person, MDM’s chief geo and a veteran geologist in his own right, Carl G. Verley, P.Geo. (University of British Columbia, 1974), a registered Professional Geoscientist with the British Columbia Association of Professional Engineers and Geoscientists.

For more information on Mountain Province Diamonds, visit www.MountainProvince.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Continental Stock Transfer & Trust Company Points the Way to a Successful Annual Meeting

One of the many services provided by New York based Continental Stock Transfer & Trust Company, the only major transfer agent specializing in smaller to midsize emerging and growth companies, is the comprehensive support of annual meetings. A successful annual meeting involves the proper carrying out of many different tasks, a number of which are required and regulated by state and federal law.

Continental’s experts stay on top of these constantly evolving rules and regulations, including U.S. Securities and Exchange Commission (SEC) requirements, to ensure correct procedures throughout the annual meeting process. Continental’s dedicated annual meeting and proxy specialists work in conjunction with client account administrators for a successful outcome.

Annual meeting services include:

• Proxy card and material design consultation

• Broker search services

• Interface with the Depository Trust & Clearing Corporation (DTCC), beneficial share proxy vendor, plan administrators and intermediaries

• Traditional and Notice-&-Access material distribution (including stratified mailings and householding)

• Online document conversion and Web hosting services

• Web hosting of proxy and annual meeting material for all constituents

• iPad®/tablet-friendly online documents with industry-leading features, including tiles

• Telephone and Internet voting platforms

• Proxy tabulation with daily online voting

• Key management reports, such as voted and unvoted lists, that help to calibrate strategy

• Material storage and fulfillment

• EDGAR and XBRL services

• Inspector of Election

• Invoice verification and processing

• Tabulation of shares voted by proxy online, by telephone or through beneficial proxy vendor

To get started, Continental provides an Annual Meeting Guide, an invaluable resource that offers important information regarding such things as the latest regulatory changes, meeting checklist and time line, sample documents, and a step-by-step description of everything a successful annual meeting requires.

For more information, visit www.ContinentalStock.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

RGS Energy (RGSE) Announces Dennis Lacey as Senior Vice President of Finance

Nationwide leader of turnkey solar energy solutions for residential, commercial, and utility customers, RGS Energy, has appointed Dennis Lacey to the new role of senior vice president of finance. He will be responsible for managing and implementing the company’s residential lease financing program.

“We welcome Dennis’ deep knowledge and executive experience in public and private equipment lease finance companies,” stated Kam Mofid, RGS Energy’s CEO. “He is an ideal executive for developing our residential solar leasing program having been the CEO of a publicly traded leasing company and having started the leasing division for a NYSE listed bank.”

Lacey brings to RGS Energy over 25 years of executive financial management experience. Previously, he held executive financial positions at Imperial Bancorp, a $6 billion publicly traded commercial bank well known for its high-tech lending practice before it was eventually acquired by Comerica. It was at Imperial Bancorp that Lacey acted as executive vice president and CFO, president of the SBA Division, and president of the Equipment Leasing Division. Before joining Imperial Bancorp, he served as president and CEO of Capital Associates, a publicly traded equipment leasing company.

In addition, Lacey previously held the role of CFO at multi-billion dollar publicly traded companies TeleTech and CKE Restaurants, as well as held the position of head of capital markets for a private investment firm engaged in aircraft leasing and other alternative asset investment and management. Earlier in his career, Lacey was an audit partner at Coopers & Lybrand.

“I am excited to join RGS Energy and lead the development of our in-house leasing program for residential solar. This new financing capability will augment our already strong relationships with third-party financiers, allowing us to accelerate growth while benefiting from the long-term ownership of the solar assets we originate and deploy. We will continue to also offer cash sales and loan options as we do today to ensure we always can meet the specific economic objectives of our customers,” commented Lacey.

To learn more about RGS Energy, please visit www.RGSEnergy.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Cellceutix Corp. (CTIX) to Initiate Psoriasis Clinical Trial

Cellceuti, a clinical-stage biopharm company developing therapies in oncology, dermatology, and antibiotic applications, reports that the U.S. Food and Drug Administration’s (FDA) 30-day waiting period pertaining to the company’s Investigational New Drug Application (“IND”) for Prurisol™ has now passed and that the company is moving toward the commencement of clinical trials of the drug candidate for the treatment of psoriasis.

“This is another significant moment for our company as we bring our third compound into clinical trials,” Cellceutix CEO Leo Ehrlich stated in the news release. “A steady stream of developments has led to a great start to 2014 for our company. We initiated a multi-center phase 2b trial of our novel antibiotic Brilacidin. The phase 1 trial of our novel anti-cancer compound Kevetrin™ is in the seventh cohort and now Prurisol™ is set to enter human trials, positioning us with three clinical drug candidates targeting three different areas of unmet medical need.”

Ehrlich further explained the company’s research to expand Brilacidin for a wide range of indications.

“We are nearing completion of IND-enabling studies of Brilacidin-OM for oral mucositis. Other pre-clinical studies of Brilacidin are ongoing for otitis and ophthalmic infections,” he stated. “Separately, in our recent acquisition of assets we acquired a library of compounds that have shown promise for Gram-negative bacterial infections. These compounds have been sent to a university laboratory in Texas for further testing. We are actively developing other acquired compounds for anti-fungal treatments. In short, while we are very pleased with the clinical development to date, we feel that there are many other areas of tremendous opportunity for our pipeline and intend to relentlessly research them to define future clinical trials.”

Cellceutix is developing Prurisol under FDA guidance that a 505(b)(2) designation is an appropriate development pathway. Upon successful completion of the crossover trial to demonstrate that Prurisol converts to abacavir in humans, the company plans to initiate a larger phase 2/3 clinical trial under a 505(b)(2) designation, which would permit Prurisol to move to advanced trials.

Cellceutix previously submitted to the FDA an application for an Orphan Drug designation for Brilacidin-OM for the prevention of oral mucositis in head and neck cancer patients. Following its review, the agency advised the company that the data would indicate that Brilacidin-OM could treat a patient population that is actually too large for an Orphan Drug designation. The company said it may narrow the focus of the application and continue the dialogue with the FDA going forward or pursue the larger market.

For more information visit www.cellceutix.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Friday, March 21, 2014

ForceField Energy, Inc. (FNRG) Primed to Capitalize on Rapidly Expanding LED Lighting Applications

ForceField Energy, a designer, seller, and distributor of energy products and solutions, has emerged as a leading participant in the global LED lighting market, which is expected to reach $25.8 billion in 2014, according to Digitimes Research. From city street lights to tennis court illumination, LED lighting applications are expanding into every industry. Even Ford Motors is jumping on the bandwagon, recently reporting that its 2015 Ford F-150 truck will feature LED headlights.

Growth in the LED market is driven by a variety of factors, including lower energy usage (10W compared to incandescent energy use of 60W, 42W with halogen, and 13W with fluorescent) and longer lifespan (40,000 hours compared to 2,000 with incandescent bulbs, 3,500 with halogen, and 8,000 with fluorescent), resulting in considerable energy cost savings. LED lights are also mercury-free and because of rigid support of internal parts are mechanically robust, making them resistant to vibration and impact, whereas most artificial light sources are highly fragile.

To capitalize on growing demand and market opportunity, the ForceField has developed a product portfolio that ranges from illumination LED lighting to LED video display systems and architectural LED lighting, as well as products for consumer use. ForceField’s portfolio is further enhanced by a series of design and utility patents, as well as various certifications and qualifications.

Production of the ForceField Energy’s products is conducted by Shanghai Lightsky Optoelectronics Technology Co. located in Shanghai. The factory supply chain consists of production line, aging line, testing line, packaging, and shipment. ForceField Energy also has a fully functioning factory where customers can come research all product lines and view the full-production process.

Industry experts forecast that within the next 5-10 years, incandescent and fluorescent fixtures around the world will be phased out and replaced by LED technology. Narrowing it down to domestic opportunity, the U.S. Department of Energy estimates that there are currently more than 2.5 billion fixtures in commercial and industrial properties in the United States alone, resulting in replacement costs of more than $1 trillion.

ForceField Energy has secured an incredible spot in the LED lighting industry at a time when more and more applications are on the horizon. If it continues to keep its pace, the company has the potential to be a household name and greatly capitalize on the latest in LED lighting use.

For more information, visit www.forcefieldenergy.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

RGS Energy (RGSE) Appoints Dennis Lacey as SVP of Finance

RGS Energy, a provider of solar energy solutions for commercial, residential, and utility customers, has named Dennis Lacey to the new position of senior vice president of finance. In this position, Lacey will be responsible for implementing and managing the company’s residential lease financing program.

“We welcome Dennis’ deep knowledge and executive experience in public and private equipment lease finance companies,” RGS Energy CEO Kam Mofid stated in the news release. “He is an ideal executive for developing our residential solar leasing program having been the CEO of a publicly traded leasing company and having started the leasing division for a NYSE listed bank.”

Lacey has more than 25 years of executive financial management experience, including holding executive financial positions at Imperial Bancorp, a $6 billion publicly traded commercial bank known for its high-tech lending practice before it was acquired by Comerica. Lacey served as Imperial Bancorp’s executive vice president and CFO, president of the SBA Division, and president of the Equipment Leasing Division.

Prior to Imperial Bancorp, Lacey also served as president and CEO of leasing company Capital Associates; CFO of multi-billion dollar publicly traded companies, TeleTech and CKE Restaurants; head of capital markets for a private investment firm engaged in aircraft leasing and other alternative asset investment and management; and as an audit partner at Coopers & Lybrand.

“I am excited to join RGS Energy and lead the development of our in-house leasing program for residential solar,” Lacey stated. “This new financing capability will augment our already strong relationships with third-party financiers, allowing us to accelerate growth while benefiting from the long-term ownership of the solar assets we originate and deploy. We will continue to also offer cash sales and loan options as we do today to ensure we always can meet the specific economic objectives of our customers.”

For more information visit www.rgsenergy.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

BG Medicine, Inc. (BGMD) Video Chart for Friday, March 21, 2014

BGMD made a big move this week, breaking through resistance and shooting up about 50 percent in the process. The chart looks like it will consolidate after the big move. This video takes a look from a retrospective view as to what traders should look for in ascending triangle patterns and talks briefly about what to look for now in the chart.

To view the video chart, visit the following link: http://www.missionir.com/videos.html

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Thursday, March 20, 2014

VolitionRx Ltd. (VNRX) Reports Noteworthy Results from Pilot Study of Its Diagnosis Tests for Prostate Cancer

Earlier this week, VolitionRx reported significant results from a pilot study of use of its NuQ® tests for diagnosis of prostate cancer. The results of the trial showed that the tests were able to detect approximately 80 percent of prostate cancer cases. Notably, they also showed that in addition to their high prostate cancer detection rate, the company’s tests are also able to differentiate between colorectal and prostate cancer.

“This is a very exciting outcome for us as we continue the development of our NuQ tests,” said Dr. Jake Micallef, Chief Scientific Officer at VolitionRx. “To have proof that with the right panel combination, NuQ tests can distinguish between different types of cancer as well as healthy samples, is just what we’ve been working towards. Detection of two major cancers with a blood test is a major milestone and a sound basis on which to investigate further cancers for panels of NuQ tests that detect and distinguish cancer diseases.”

The NuQ tests are able to make this distinction via detection of levels of epigenetically altered circulating nucleosomes in each sample, the structure of which Volition has found to be different in the two different types of cancer. As an illustration, VolitionRx mentions that the “levels of circulating nucleosomes containing H3K9(Me)3 were elevated in colorectal cancer, but supressed in prostate cancer”. This is an indicator of the NuQ ELISA tests’ ability to detect both cancer types.

Dr. Micallef will be presenting a poster at The International Society of Oncology and Biomarkers Congress (ISOBM) in Barcelona, Spain. There he will share results of the latest study into the effectiveness of NuQ® assays as an initial screening tool in detecting colorectal and now prostate cancer.

VolitionRx is carrying out several clinical trials on the effectiveness of the NuQ® assays as a cancer diagnostic tool:

• A 4,800-patient retrospective study and an 11,000 patient prospective study into colorectal cancer at Hvidovre Hospital, University of Copenhagen, Denmark.

• A 2,000-patient prospective study that involves patients with the 20 most prevalent cancers at University Hospital in Bonn, Germany.

• A 250-patient study into colorectal cancer at CHU-UCL Mont Godinne Hospital, Belgium.

Another recent trial documented that VolitionRx’s NuQ assays were able to detect over 85 percent of colorectal cancer cases with over 85 percent specificity. This earlier study had taken samples from healthy subjects as well as patients recently diagnosed with colorectal cancer.

A life sciences company focused on developing blood-based diagnostic tests for different types of cancer, VolitionRx seeks to provide diagnostic tests as common and easy-to-use as mainstream as diabetes and cholesterol tests for patient and doctor use.

For more information, visit: www.volitionrx.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Placement of CASMED’s (CASM) FORE-SIGHT Cerebral Oximeter Reaches 1,000

Noninvasive patient monitoring medical devices leader CAS Medical Systems, Inc. (CASMED) announced the global cumulative net shipment total for its FORE-SIGHT Cerebral Oximeters reached 1,000 last week. The total includes monitors installed at nine of the top 20 cardiac surgery centers in United States and three of the country’s top 10 pediatric centers. CASMED previously announced a net cumulative total of 935 units as of Dec. 31, 2013.

Achieving this milestone denotes the continued market acceptance strength of the FORE-SIGHT ELITE monitor, which CASMED introduced in September 2013. The cumulative sales of the company’s disposable oximetry sensors has surpassed 300,000, meaning more than 150,000 patients – adults, children, and newborns – have benefited from FORE-SIGHT technology.

“Improving patient care is one of CASMED’s core values,” said CASMED President and CEO Tom Patton, “and it is rewarding to know that with FORE-SIGHT oximetry we have enabled clinicians around the world to provide better outcomes for so many people.”

CASMED recently added four U.S. direct sales representatives to its team in response to growing demand for the company’s products and increasing interest in cerebral oximetry. The new representatives will handle territories that have previously been under-represented by independent distributors. This brings CASMED’s U.S. distribution team to nine direct reps and three manufacturer’s rep organizations.

For more information, visit www.casmed.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Wednesday, March 19, 2014

VistaGen Therapeutics, Inc. (VSTA) Targeting Nation’s No. 1 Killer with Proprietary 3D Bioassay System

Despite decades of awareness and prevention campaigns, heart disease remains the No. 1 cause of death for both men and women, killing more than 600,000 Americans each year. Roughly 49 percent of Americans have at least one of the three risk factors for heart disease: high blood pressure, high LDL cholesterol and smoking, according to the Center for Disease Control. What’s astounding is that an overwhelming majority of heart disease is the result of poor lifestyle choices. While it’s certainly nothing to celebrate, the statistics are keeping scientists on their toes and companies like VistaGen in business.

VistaGen is an innovative life sciences company leveraging its Human Clinical Trials in a Test Tube™ technology platform to provide clinically relevant predictions of potential toxicity of promising new drug candidates. One of VistaGen’s particular areas of focus is on cardiovascular care.

It is estimated that about one-third of all potential new drugs candidates fail in preclinical or clinical development due to unexpected safety concerns. Countless human lives have been lost because “promising” cardiovascular drugs were discontinued because of late-stage failure. Using human heart cells derived from human pluripotent stem cells (hPSCs), VistaGen’s technology is designed to address potential toxicity of new cardiovascular drug candidates long before they are ever tested in humans.

VistaGen’s strategy is to pair CardioSafe 3D™ with modern medicinal chemistry to build a pipeline of novel, safer chemical variants (Drug Rescue Variants™) of once-promising drug candidates that initially were developed by biotechnology and pharmaceutical companies, but that were later abandoned due to the aforementioned concerns.

For more information visit www.vistagen.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

LD Micro Unveils Significant Changes to Two Key Annual Investor Conference Events

LD Micro this year will host its 4th annual Invitational as well as its 7th annual Main Event, each of which have been revamped for efficiency and impact. Registration is currently underway, which special pricing available until March 31. As usual, companies that presented in the past will have first option to sign up for the coming year.

First up is the LD Micro Invitation, scheduled for June 4, 2014. LD Micro will host 80 companies at this year’s Invitational event, expanding the presentation field to serve a larger audience.

While demand for attending LD Micro events is on the rise, the goal of the conferences is to focus on quality over quantity. To this accord, LD Micro is decreasing the size of its two-day Main Event which is set to take place in December. Main Event will host 180 companies, 160 of which will make presentations, with the remaining spots designated exclusively available for 1x1s. This will enable great focus and highlight on the top names in the micro-cap space.

In addition, for the first time, the bi-monthly LD Micro Newsletter will be open to the public. The newsletter features unique write-ups, interviews, and opinions from renowned as well as under-the-radar contributors.

“The one thing all contributors have in common is that they have something important to say. The goal is to make it an easy read, and one that will leave you smiling at the end,” Chris Lahiji, founder and president of LD Micro said in the announcement.

All executives that participate in LD Micro events will receive the newsletter at no cost. It’s important to note that all attendees must subscribe to our annual newsletter in order to be considered for admission.

For individuals, newsletter subscription is $395 per year; for college students or individuals that belong to the Micro-Cap Club (http://microcapclub.com), subscription is complementary.

“I’ve never been more excited in my career, and have built quite the arsenal of talent and insight that you cannot find anywhere else,” says Lahiji.

Sponsorship opportunities are also available, though existing sponsors have first option to participate in both events.

For more information, visit www.ldmicro.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Ceragon Networks Ltd. (CRNT) Lands Multi-Million Deal to Build High-Cap Wireless Network for India’s Biggest Oil and Gas E&P

Ceragon Networks, a dominant force in the world of high-capacity wireless backhaul and fronthaul, reported big news today that the company has been selected by massive Indian oil and gas company, Oil and Natural Gas Corp. Ltd. (NSE: ONGC), to design and engineer a new high-cap network backbone to replace their existing VSAT connections for onshore/offshore sites.

Really the perfect company to handle this sort of job, as CRNT is known the world over for their ability to deliver solutions which have enabled countless providers to extend 2G/3G, 4G/LTE, and other broadband services to their respective customer bases. CRNT’s reputation for robust high-cap microwave nodes that are designed for all-outdoor conditions, combined with modular aggregation node hardware and their CeraOS unified operating system, which spans the entire FibeAir IP-20 platform, are key elements of the company’s reputation that helped produce this deal and they really have helped to distinguish the company as a clear leader in high-cap wireless hauling.

This is a pretty major undertaking for CRNT, despite their size and proficiency, given that ONGC is responsible for nearly 70% of India’s crude production and as much as 60% of the gas, doing something like 1.2M BOEPD with a market cap in the neighborhood of $38.57B, there is a huge logistical envelope to address via this new backbone system. By going to a much more stable wireless backbone than the existing satellite phones, one based on CRNT’s field-proven Evolution™ Long Haul multicarrier microwave radio hardware, ONGC will be picking up massive Mbps throughput for substantially reduced overall cost-per-bit.

In addition to these powerful Evolution nodes, which allow operators like ONGC to migrate seamlessly from legacy time-division multiplexed architectures to an all-IP framework, CRNT will provide a comprehensive suite of supplemental services ranging from site-surveying to project management and installation, ultimately delivering the new turnkey backbone to ONGC for a sticker price pegged somewhere in the ballpark of several million dollars. The backbone network will be used to handle mission critical aspects of ONGC’s operations like SCADA and their video surveillance systems, as well as providing IT services across all of the company’s numerous sites, including web access, email, video conferencing, and SAP apps.

President and CEO of CRNT, Ira Palti, emphasized how operators in the oil and gas industry are racing these days to get their hands on robust data handling solutions in order to support the growing variety of value-added services they need, both to execute on operational objectives and to stay ahead of their competition. Palti expressed supreme confidence in ONGC’s decision to go with the company for their backbone network and added that CRNT’s high-cap range of microwave solutions were ideal for this particular market, considering how they have over three decades of experience in the game and have developed products like their marine-grade PointLink system, which combines high power radios with gyro-stabilized antennas to provide the most reliable high-cap integrated solution on the market today, precisely for such operations as offshore oil and gas E&P.

Palti further emphasized CRNT’s proven service and project management expertise, asserting that blue-chip clients like ONGC can expect to enjoy the fullest range of support for their businesses possible, with a truly comprehensive service package that benefits from Cergaon’s considerable experience, especially when it comes to the oil and gas sector. Plati isn’t just whistling Dixie here either, as CRNT has solutions deployed in over 130 countries worldwide, representing over 430 service providers which are no doubt well-acquainted with just how comprehensive Cergaon’s support services can be.

Visit the Ceragon Networks Ltd. website for more info at www.Ceragon.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Zix Corp. (ZIXI) and Goodwin House Renew Contract for Email Security Solution

Zix announced today that it has renewed its contract with Goodwin House for a period of five years. Goodwin House has used Zix Email Encryption since 2010 to securely communicate protected health information for the residents in its retirement communities in Virginia.

Goodwin House uses ZixGateway® to protect its residents’ privacy and comply with the Health Insurance Portability and Accountability Act (HIPAA). ZixGateway is a policy-based email encryption service that automatically scans and encrypts outbound email containing sensitive information. Its ease of use and proven scanning and detection capabilities were the top factors in Goodwin House’s decision to renew the contract with ZixCorp.

“Protecting our residents’ privacy is essential to maintaining their trust and providing the quality services they expect from our organization,” said David Fowler, Director of Information Technology for Goodwin House. “We recognize the importance of communicating health information securely and require a solution that our employees can use comfortably on a daily basis. Not only does ZixCorp’s solution make secure email easy for our employees, but its policies prevent disclosure errors with automatic scanning and encryption, providing added reassurance that our residents’ valuable information is protected.”

ZixCorp’s technology employs sophisticated lexicons to properly identify and protect sensitive information identified by healthcare, research, financial, and insurance industries. The company’s lexicons can also identify social security numbers, profanity, and personal information protected by state regulations.

“More than 15 years of experience in email encryption, along with our dedication to innovation, has allowed us to refine an out-of-the-box solution that customers can deploy in a day and confidently use for years to come,” said Rick Spurr, ZixCorp’s Chairman and Chief Executive Officer. “Every component is critical to making the industry’s easiest to use solution, and we appreciate Goodwin House for seeing the value in our email encryption and continuing to rely on ZixCorp to meet their email data protection and compliance needs.”

For more information on ZixCorp, please visit www.zixcorp.com.

For more information on Goodwin House and its residential services, please visit www.goodwinhouse.org.

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html